Soligenix (Nasdaq: SNGX) has secured a high-priority Type A meeting with the FDA to discuss a second Phase 3 study for its groundbreaking HyBryte™ treatment for early-stage cutaneous T-cell lymphoma (CTCL), a rare cancer. The first Phase 3 trial yielded statistically significant results, and the innovative photodynamic therapy uses safe visible light activation, avoiding the risks associated with ultraviolet exposure. With orphan drug and fast track designations from the FDA and orphan designation from the EMA, investors should stay tuned for further updates on this promising development in CTCL treatment.

Reviva Pharmaceuticals (Nasdaq: RVPH) presented data on its novel serotonin-dopamine stabilizer, brilaroxazine, at the prestigious ISID Meeting in Tokyo. The preclinical data shows promising results in reducing psoriasis severity and associated biomarkers. With a well-tolerated safety profile and proven efficacy in schizophrenia patients, brilaroxazine lipogel could revolutionize the treatment landscape for psoriasis – a condition affecting 125 million people worldwide. Reviva plans to submit an investigational new drug application for brilaroxazine lipogel in psoriasis in 2024.

Inspira Technologies' (Nasdaq: IINN) latest innovation, the VORTX™ Blood Oxygenator., aims to revolutionize acute respiratory care. This breakthrough technology is designed to imitate lung function by efficiently saturating blood with oxygen and removing carbon dioxide. With the potential to transform the $1.16 billion perfusionists systems market, the VORTX™ Blood Oxygenator targets around two million extracorporeal procedures per year, including open-heart surgeries and ECMO treatments.

ASP Isotopes Inc. (NASDAQ:ASPI) announced a significant supply agreement for highly enriched Carbon-14 with Canadian company RC-14. The contract, worth a minimum annual revenue of approximately $2.5 million and targeted annual revenue of approximately $3.8 million, will involve enriching Carbon-14 at ASP Isotopes' Light Isotope Enrichment Facility in South Africa. With production expected to commence in 2H 2023, this deal positions ASP Isotopes as a vital alternative supplier of Carbon-14, a critical radiolabel in drug discovery and metabolism. This strategic partnership aims to address global supply chain issues and offers investors an enticing opportunity in the advanced materials sector.